SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-103981
Filing Date
2024-09-05
Accepted
2024-09-05 16:07:47
Documents
46
Period of Report
2024-07-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-20240731.htm   iXBRL 10-Q 928926
2 EX-10.1 kalv-ex10_1.htm EX-10.1 506092
3 EX-10.2 kalv-ex10_2.htm EX-10.2 167268
4 EX-31.1 kalv-ex31_1.htm EX-31.1 17147
5 EX-32.1 kalv-ex32_1.htm EX-32.1 8124
  Complete submission text file 0000950170-24-103981.txt   4844715

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kalv-20240731.xsd EX-101.SCH 584055
48 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20240731_htm.xml XML 618081
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 241281463
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)